TrianglePUBLICATIONS · 18235122
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2008 Feb 1
- First author
- Blanke CD
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Blanke CD
- type
- Author
- name
- Rankin C
- type
- Author
- name
- Demetri GD
- type
- Author
- name
- Ryan CW
- type
- Author
- name
- von Mehren M
- type
- Author
- name
- Benjamin RS
- type
- Author
- name
- Raymond AK
- type
- Author
- name
- Bramwell VH
- type
- Author
- name
- Baker LH
- type
- Author
- name
- Maki RG
- type
- Author
- name
- Tanaka M
- type
- Author
- name
- Hecht JR
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Blanke CD
- type
- Author
- name
- Rankin C
- type
- Author
- name
- Demetri GD
- type
- Author
- name
- Ryan CW
- type
- Author
- name
- von Mehren M
- type
- Author
- name
- Benjamin RS
- type
- Author
- name
- Raymond AK
- type
- Author
- name
- Bramwell VH
- type
- Author
- name
- Baker LH
- type
- Author
- name
- Maki RG
- type
- Author
- name
- Tanaka M
- type
- Author
- name
- Hecht JR
- type
- Author
- bibliography ids
- nci-bib-fea9d948a8905d8bcc2a6720
- book metadata
- content sha256
- 47540b3fc2a5eaab615c303123d86ed9c81602aa07dfddacabb19a36af7603ea
- document type
- citation
- dois
- 10.1200/JCO.2007.13.4452
- electronic publication date
- display
- Source null
- precision
- missing
- year
- Source null
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:18235122
- immutable id
- pubmed:18235122@47540b3fc2a5eaab615c303123d86ed9c81602aa07dfddacabb19a36af7603ea
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- 1527-7755
- issn print
- 0732-183X
- issue
- 4
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 626-32
- volume
- 26
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 18235122
- provenance
- batch id
- e663b4be92ee60a9b059
- provider
- NCBI PubMed ESummary
- record sha256
- 0a3dad379b5746c6a3cdcd2f58cea4be883812e4cdbc8dcc60d1f3d31c65b77a
- response sha256
- 514286e846d1566a3f75c88a4af66b82adfc16ee2368b19bce657f2237aba90d
- retrieved at
- 2026-09-09T23:46:19.265979+00:00
- publication date
- display
- 2008 Feb 1
- precision
- day
- year
- 2008
- publication types
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
Preserved source evidence · Not medical advice